MX2017005055A - Compuesto que tiene actividad agonistica de gpr119, metodo para preparar el mismo y composicion farmaceutica que incluye el mismo componente efectivo. - Google Patents

Compuesto que tiene actividad agonistica de gpr119, metodo para preparar el mismo y composicion farmaceutica que incluye el mismo componente efectivo.

Info

Publication number
MX2017005055A
MX2017005055A MX2017005055A MX2017005055A MX2017005055A MX 2017005055 A MX2017005055 A MX 2017005055A MX 2017005055 A MX2017005055 A MX 2017005055A MX 2017005055 A MX2017005055 A MX 2017005055A MX 2017005055 A MX2017005055 A MX 2017005055A
Authority
MX
Mexico
Prior art keywords
same
preparing
pharmaceutical composition
composition including
effective component
Prior art date
Application number
MX2017005055A
Other languages
English (en)
Inventor
Young AHN Chi
Young Lee Jae
Kyung Kim Mi
Rim Baek Gye
Jung KIM Yoon
Hoon JUNG Il
Mi Kang So
Ju Lee Hyo
Hwang Cheong Ye
Hyoung Kim Tae
Kyoung Yang Eun
Ho Son Moon
Yell Shin Chang
Sung Yang Jae
Na Chae Yu
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Priority claimed from PCT/KR2015/007715 external-priority patent/WO2016068453A1/en
Publication of MX2017005055A publication Critical patent/MX2017005055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con un nuevo compuesto que tiene una actividad agonística de GPR119, con un método para preparar la misma y con una composición farmacéutica que incluye la misma como un componente efectivo. La presente invención tiene una acción hipoglucémica efectiva y un efecto sobre las células beta pancreáticas, y también mejora el metabolismo de lípidos que es un factor de riesgo cardiovascular crónico, por lo que tiene un efecto de tratamiento y/o prevención de una enfermedad metabólica, tal como diabetes.
MX2017005055A 2014-10-27 2015-07-24 Compuesto que tiene actividad agonistica de gpr119, metodo para preparar el mismo y composicion farmaceutica que incluye el mismo componente efectivo. MX2017005055A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20140146462 2014-10-27
KR1020150090708A KR101726819B1 (ko) 2014-10-27 2015-06-25 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
PCT/KR2015/007715 WO2016068453A1 (en) 2014-10-27 2015-07-24 Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component

Publications (1)

Publication Number Publication Date
MX2017005055A true MX2017005055A (es) 2017-07-04

Family

ID=56020446

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005055A MX2017005055A (es) 2014-10-27 2015-07-24 Compuesto que tiene actividad agonistica de gpr119, metodo para preparar el mismo y composicion farmaceutica que incluye el mismo componente efectivo.

Country Status (19)

Country Link
US (1) US10428055B2 (es)
EP (1) EP3212640B1 (es)
JP (1) JP6470408B2 (es)
KR (1) KR101726819B1 (es)
CN (1) CN107074838B (es)
AU (1) AU2015337407B2 (es)
BR (1) BR112017007692A2 (es)
CA (1) CA2959714C (es)
ES (1) ES2758981T3 (es)
HU (1) HUE047563T2 (es)
IL (1) IL251456A0 (es)
MX (1) MX2017005055A (es)
NZ (1) NZ729455A (es)
PH (1) PH12017500795A1 (es)
PL (1) PL3212640T3 (es)
PT (1) PT3212640T (es)
RU (1) RU2670197C1 (es)
SA (1) SA517381341B1 (es)
SG (1) SG11201701347WA (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020055170A1 (ko) * 2018-09-12 2020-03-19 동아에스티 주식회사 Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2021071837A1 (en) * 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
CA3167630A1 (en) * 2020-03-11 2021-09-16 Dong-A St Co., Ltd. Pharmaceutical composition comprising a gpr119 agonist and a hypoglycemic agent for prevention or treatment of diabetes and metobolic diseases associated therewith
MX2022011128A (es) * 2020-03-11 2022-10-13 Dong A St Co Ltd Composicion farmaceutica para la prevencion o el tratamiento de la esteatohepatitis no alcoholica.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO1645B1 (en) 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
US5364865A (en) 1992-12-30 1994-11-15 Sterling Winthrop Inc. Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
TW200416221A (en) * 2002-10-30 2004-09-01 Vertex Pharma Compositions useful as inhibitors of ROCK and other protein kinases
WO2007003962A2 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
ES2522587T3 (es) 2006-12-05 2014-11-17 Arena Pharmaceuticals, Inc. Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
RS52065B (en) 2007-01-04 2012-06-30 Prosidion Ltd PIPERIDINSKI GPCR AGONIST
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
JP5309216B2 (ja) 2008-07-11 2013-10-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての４−フェノキシメチルピペリジン類
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2016068453A1 (en) * 2014-10-27 2016-05-06 Dong-A St Co., Ltd. Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component

Also Published As

Publication number Publication date
AU2015337407B2 (en) 2018-11-08
BR112017007692A2 (pt) 2017-12-19
RU2670197C1 (ru) 2018-10-19
PL3212640T3 (pl) 2020-05-18
PT3212640T (pt) 2019-12-06
NZ729455A (en) 2018-09-28
EP3212640A1 (en) 2017-09-06
US20190092763A1 (en) 2019-03-28
AU2015337407A1 (en) 2017-03-16
EP3212640A4 (en) 2018-04-25
KR101726819B1 (ko) 2017-04-13
JP6470408B2 (ja) 2019-02-13
CA2959714A1 (en) 2016-05-06
PH12017500795B1 (en) 2017-10-02
SA517381341B1 (ar) 2020-09-21
CN107074838B (zh) 2021-03-19
US10428055B2 (en) 2019-10-01
JP2017533213A (ja) 2017-11-09
CN107074838A (zh) 2017-08-18
EP3212640B1 (en) 2019-11-06
CA2959714C (en) 2020-08-18
HUE047563T2 (hu) 2020-04-28
PH12017500795A1 (en) 2017-10-02
KR20160049434A (ko) 2016-05-09
SG11201701347WA (en) 2017-03-30
ES2758981T3 (es) 2020-05-07
IL251456A0 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
WO2016068453A8 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12017502228A1 (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
MX2018005096A (es) Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
BR112015022197A2 (pt) tratamento de cataplexia
PH12017500795A1 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
MX370032B (es) Agonistas del receptor de esfingosina-1-fosfato, metodos para prepararlos y composiciones farmaceuticas que contienen los mismos como un agente activo.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
TN2018000038A1 (en) Inhibitor of the mutated isocitrate dehydrogenase idh1 r132h
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2014036528A3 (en) Agents useful for treating obesity, diabetes and related disorders
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112017013015A2 (pt) método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
PH12017501735A1 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
WO2016168388A3 (en) Therapies for obesity, diabetes and related indications
MX2018004489A (es) Extracto de agavaceae que comprende saponinas esteroidales y su uso para tratar y/o prevenir patologías relacionadas con desórdenes metabólicos.
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
WO2011111066A3 (en) Composition and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration